ATE333868T1 - Verwendung von pyridoxamin für die behandlung und unterdrückung von komplikationen im zusammenhang mit adipositas - Google Patents

Verwendung von pyridoxamin für die behandlung und unterdrückung von komplikationen im zusammenhang mit adipositas

Info

Publication number
ATE333868T1
ATE333868T1 AT01992569T AT01992569T ATE333868T1 AT E333868 T1 ATE333868 T1 AT E333868T1 AT 01992569 T AT01992569 T AT 01992569T AT 01992569 T AT01992569 T AT 01992569T AT E333868 T1 ATE333868 T1 AT E333868T1
Authority
AT
Austria
Prior art keywords
obesity
pyridoxamine
suppression
treatment
product formation
Prior art date
Application number
AT01992569T
Other languages
English (en)
Inventor
John Baynes
Original Assignee
Univ South Carolina
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ South Carolina filed Critical Univ South Carolina
Application granted granted Critical
Publication of ATE333868T1 publication Critical patent/ATE333868T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • External Artificial Organs (AREA)
AT01992569T 2000-11-02 2001-11-02 Verwendung von pyridoxamin für die behandlung und unterdrückung von komplikationen im zusammenhang mit adipositas ATE333868T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24563000P 2000-11-02 2000-11-02
US31578901P 2001-08-29 2001-08-29

Publications (1)

Publication Number Publication Date
ATE333868T1 true ATE333868T1 (de) 2006-08-15

Family

ID=26937355

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01992569T ATE333868T1 (de) 2000-11-02 2001-11-02 Verwendung von pyridoxamin für die behandlung und unterdrückung von komplikationen im zusammenhang mit adipositas

Country Status (6)

Country Link
US (1) US20020128295A1 (de)
EP (1) EP1341532B1 (de)
AT (1) ATE333868T1 (de)
AU (1) AU2002218002A1 (de)
DE (1) DE60121794D1 (de)
WO (1) WO2002036109A2 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7030146B2 (en) * 1996-09-10 2006-04-18 University Of South Carolina Methods for treating diabetic neuropathy
WO2001013900A2 (en) 1999-08-24 2001-03-01 Medicure International Inc. Compositions for the treatment of cardiovascular diseases containing pyridoxal compounds and cardiovascular compounds
US7442689B2 (en) 2000-02-29 2008-10-28 Medicure International Inc. Cardioprotective phosphonates and malonates
US20090082407A1 (en) * 2004-06-18 2009-03-26 Biostratum, Inc. Pyridoxamine for the Treatment of Diabetic Kidney Disease
PL1643999T3 (pl) * 2003-06-20 2012-02-29 Nephrogenex Inc Pirydoksamina do zastosowania w leczeniu nefropatii cukrzycowej w cukrzycy typu II
WO2005077902A2 (en) * 2004-02-09 2005-08-25 Biostratum, Inc. Methods for the synthesis of pyridoxamine
JPWO2006028007A1 (ja) * 2004-09-06 2008-05-08 興和株式会社 糸球体疾患治療剤
DE102004050353A1 (de) * 2004-10-15 2006-04-20 Basf Ag Verwendung stabiler Ammoniumsalze der Liponsäure zur Behandlung diabetischer und weiterer Störungen
US10975033B2 (en) * 2011-07-12 2021-04-13 Vanderbilt University Methods for treating inflammation and hypertension with γ-ketoaldehyde skavengers
HUE066390T2 (hu) 2017-04-27 2024-07-28 Univ Vanderbilt Eljárások ateroszklerózis kezelésére gamma-ketoaldehid-szkevendzserekkel

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5288716A (en) * 1987-02-18 1994-02-22 Ulrich Speck Use of pyridoxine derivatives in the prevention and treatment of hyperlipidaemia and atherosclerosis
US6228858B1 (en) * 1995-09-12 2001-05-08 University Of Kansas Medical Center Advanced glycation end-product intermediaries and post-amadori inhibition
AU1112500A (en) * 1998-10-14 2000-05-01 Kansas University Medical Center Research Institute, Inc. Methods for inhibiting diabetic complications
ATE241982T1 (de) * 1998-10-22 2003-06-15 Univ South Carolina Verfahren zur hemmung von diabetischen komplikationen

Also Published As

Publication number Publication date
EP1341532B1 (de) 2006-07-26
EP1341532A2 (de) 2003-09-10
US20020128295A1 (en) 2002-09-12
WO2002036109A2 (en) 2002-05-10
AU2002218002A1 (en) 2002-05-15
WO2002036109A3 (en) 2003-05-30
DE60121794D1 (de) 2006-09-07

Similar Documents

Publication Publication Date Title
DE69526937D1 (de) Verwendung von methanbisphosphonsäurederivaten zur behandlung von aufgelockerten prothesen
DE60121794D1 (de) Verwendung von pyridoxamin für die behandlung und unterdrückung von komplikationen im zusammenhang mit adipositas
DE60042172D1 (de) Verfahren und zusammensetzungen zur vorbeugung oder behandlung von atherosclerose, restenose und zusammenhängenden erkrankungen
DK0763055T3 (da) Perflouralkylketon-inhibitorer af elastase og fremgangsmåde til fremstilling deraf
DE69924641D1 (de) Behandlung von asthma anhand von mek-inhibitoren
UA49869C2 (uk) Нафтил-заміщені похідні бензимідазолу, фармацевтична композиція, спосіб лікування (варіанти) та спосіб інгібування людського фактора
ATE375341T1 (de) Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen
NZ515567A (en) Method for treating chronic pain using MEK inhibitors
ATE222488T1 (de) Verwendung von anti-vegf-mitteln zur behandlung der endometriose
ATE177421T1 (de) Wasserlösliches nimesulid-salz, sowie dessen verwendung zur behandlung von entzündungen
DE69805973D1 (de) Behandlung von herzrythmusstörungen durch hemmung einer multifunktionalen calcium/calmodulin-abhängigen protein kinase
ATE400301T1 (de) Arteriovenöse und venöse transplantatbehandlungen: methoden und zusammensetzungen
PL322134A1 (en) Trisubstituted phenyl derivatives
ATE412646T1 (de) Zur behandlung von schmerzen geeignete therapeutische mittel
DE69834024D1 (de) Tetracycline verbindungen zur behandlung von spezifischen krebsarten
ATE309795T1 (de) Acetylcholinesteraseinhibitoren zur behandlung und diagnose von atemstörungen während des schlafes
DE69634404D1 (de) Caroteinoid-nicotinamid-zink zusammensetzungen und verfahren zur behandlung unter verwendung derselben
DE69713620D1 (de) Verwendung von arachidonsäure und/oder docohexaensäure zur herstellung eines arzneimittels zur behandlung von dyspraxia
ATE429916T1 (de) Verwendung von sulfonamid-derivaten bei der behandlung von adipositas oder zur verringerung der nahrungsaufnahme
ATE222119T1 (de) Verwendung von erythropoietin zur behandlung von multiple myelom
ATE271873T1 (de) Verwendung von glukosamin und glukosaminderivaten zur schnellen linderung von juckreiz oder lokalisiertem schmerz
DE60036122D1 (de) Verwendung von eplerenon zur behandlung von restenose
CA2341638A1 (en) Use of a midkine inhibitor
ATE361071T1 (de) Verwendung von irbesartan zur vorbeugung oder behandlung pulmonaler hypertonie
NO952601L (no) Oligonukleotider for inhibering av ekspresjon av isoprenylprotein-transferaser

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties